keyword
MENU ▼
Read by QxMD icon Read
search

Gliosarcoma

keyword
https://www.readbyqxmd.com/read/28812310/gliosarcoma-arising-from-oligodendroglioma-idh-mutant-and-1p-19q-codeleted
#1
Takayuki Yasuda, Masayuki Nitta, Takashi Komori, Tatsuya Kobayashi, Kenta Masui, Takashi Maruyama, Tatsuo Sawada, Yoshihiro Muragaki, Takakazu Kawamata
Herein, we present a rare case of gliosarcoma arising from oligodendroglioma, isocitrate dehydrogenase (IDH) mutant and 1p/19q codeleted. A 36-year-old man presented with a non-enhanced calcified abnormal lesion on the right frontal lobe. The patient underwent subtotal surgical resection, PAV chemotherapy (procarbazine, nimustine (ACNU) and vincristine), and fractionated radiotherapy with 50 Gy. The pathological diagnosis was oligodendroglioma, IDH mutant and 1p/19q codeleted, World Health Organization 2016 grade II...
August 15, 2017: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/28776680/genistein-exerts-potent-antitumour-effects-alongside-anaesthetic-propofol-by-suppressing-cell-proliferation-and-nuclear-factor-%C3%AE%C2%BAb-mediated-signalling-and-through-upregulating-microrna-218-expression-in-an-intracranial-rat-brain-tumour-model
#2
Yuzhen Zheng, Haigen Liu, Yu Liang
OBJECTIVE: This study was implemented to evaluate the effect of genistein and propofol on intracranial tumour model. METHODS: Male Fischer 344 rats were subjected to intracranial implantation of 9L gliosarcoma cells. Genistein (100 or 200 mg/kg b.wt) was administered orally regularly from 3rd day after implantation to 25th day. Propofol (20 mg/kg; i.p.) was administered once every 5 days till 25th day and was administered 2 h after genistein. KEY FINDINGS: Human gliosarcoma cells (U251) exposed to genistein (12...
August 4, 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28775171/gliosarcomas-with-the-braf-v600e-mutation-a-report-of-two-cases-and-review-of-the-literature
#3
Leiming Wang, Jian Sun, Zhuo Li, Li Chen, Yongjuan Fu, Lihong Zhao, Li Liu, Yukui Wei, Lianghong Teng, Dehong Lu
Gliosarcoma, which is regarded as a variant of glioblastoma, is a rare malignant neoplasm of the central nervous system. Both its sarcomatous component and glial component are reported to share significant clinical and genetic similarities. However, gliosarcomas are considered to be characterised by a lack of the BRAF V600E mutation. Here, we report two cases of gliosarcoma harbouring the BRAF V600E mutation, of which one case appears to have arisen de novo, while the other likely arose from ganglioglioma. Interestingly, the BRAF V600E mutation was detected only in the glial component in the first case, but was present in both the glial and the sarcomatous components in the recurrent gliosarcoma...
August 3, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28756069/gliosarcoma-in-septuagenarians-and-octogenarians-what-is-the-impact-of-adjuvant-chemoradiation
#4
Jacob Y Shin, Ja Kyoung Yoon, Aidnag Z Diaz
The objective of our study is to determine the impact of adjuvant chemoradiation on overall survival (OS) for gliosarcoma in septuagenarians and octogenarians. Data were extracted from the National Cancer Data Base (NCDB). Chi-square test, Kaplan-Meier method, and Cox regression models were employed in SPSS 23.0 (Armonk, NY: IBM Corp.) for data analyses. 210 patients with gliosarcoma who underwent resection were identified. 168 (80.0%) patients received adjuvant chemoradiation, and 42 (20.0%) received adjuvant RT alone...
July 26, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28748342/non-canonical-idh1-and-idh2-mutations-a-clonal-and-relevant-event-in-an-italian-cohort-of-gliomas-classified-according-to-the-2016-world-health-organization-who-criteria
#5
Michela Visani, Giorgia Acquaviva, Gianluca Marucci, Alexandro Paccapelo, Antonella Mura, Enrico Franceschi, Daniela Grifoni, Annalisa Pession, Giovanni Tallini, Alba A Brandes, Dario de Biase
According to the 2016 World Health Organization (WHO) classification of tumors of the central nervous system, assessment of exon 4 mutations in isocitrate dehydrogenase 1 or 2 genes (IDH1 or IDH2) is an essential step in the characterization of gliomas. The p.R132H mutation is the most frequent alteration in IDH genes, however other non-canonical IDH mutations can be identified. The aim of this study is to investigate in depth the prevalence of non-R132H IDH ("non-canonical") mutations in brain tumors classified according to the 2016 WHO scheme and their clonal distribution in neoplastic cells...
July 26, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28738724/neighbor-effect-penumbra-dose-exposed-neighbor-cells-contribute-to-the-enhanced-survival-of-high-dose-targeted-cells
#6
Min-Ho Lee, Ki-Man Lee, Eun-Hee Kim
PURPOSE: In the last decade, new types of 'bystander effect' have been suggested by multiple research groups and have been challenged by others. In this study, we explored a new type of bystander effect, which has been defined in previous studies as the enhancement of the survival of high-dose targeted cells due to the penumbra-dose exposed neighbor cells. Intensity-modulated radiation therapy, which is the most widely used treatment modality, generates local regions of gradient doses between targeted and shielded cells throughout the treatment volume; therefore, we were urged to ascertain whether the new type of effect is real and to suggest a revised treatment planning...
August 16, 2017: International Journal of Radiation Biology
https://www.readbyqxmd.com/read/28644110/detailed-magnetic-resonance-imaging-features-of-a-case-series-of-primary-gliosarcoma
#7
Luísa Sampaio, Paulo Linhares, José Fonseca
Objective We aimed to characterise the magnetic resonance imaging (MRI) features of a case series of primary gliosarcoma, with the inclusion of diffusion-weighted imaging and perfusion imaging with dynamic susceptibility contrast MRI. Materials and methods We conducted a retrospective study of cases of primary gliosarcoma from the Pathology Department database from January 2006 to December 2014. Clinical and demographic data were obtained. Two neuroradiologists, blinded to diagnosis, assessed tumour location, signal intensity in T1 and T2-weighted images, pattern of enhancement, diffusion-weighted imaging and dynamic susceptibility contrast MRI studies on preoperative MRI...
January 1, 2017: Neuroradiology Journal
https://www.readbyqxmd.com/read/28642179/analysis-of-outcomes-of-multidisciplinary-management-of-gliosarcoma-a-single-centre-study-2000-2013
#8
Abhinav Jain, Jason Correia, Patrick Schweder, Adele McMahon, Joseph Merola, Robert Aspoas
BACKGROUND: Gliosarcoma is a rare CNS tumour with a reported incidence of ∼2-8% of all gliomas. We reviewed the outcomes of patients treated at our institution over a 14-year period from 2000-2013 to characterize overall and progression free survival as well as to elucidate the additive effect of chemo-radiotherapy. METHODS: For the duration of 01/01/2000 to 31/12/2013, we retrospectively reviewed the clinical notes of all patients treated at our institution with a histopathological diagnosis of Gliosarcoma...
June 19, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28621623/patterns-of-care-and-outcomes-in-gliosarcoma-an-analysis-of-the-national-cancer-database
#9
Jonathan Frandsen, Andrew Orton, Randy Jensen, Howard Colman, Adam L Cohen, Jonathan Tward, Dennis C Shrieve, Gita Suneja
OBJECTIVE The authors compared presenting characteristics and survival for patients with gliosarcoma (GS) and glioblastoma (GBM). Additionally, they performed a survival analysis for patients who underwent GS treatments with the hypothesis that trimodality therapy (surgery followed by radiation and chemotherapy) would be superior to nontrimodality therapy (surgery alone or surgery followed by chemotherapy or radiation). METHODS Adults diagnosed with GS and GBM between the years 2004 and 2013 were queried from the National Cancer Database...
June 16, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28558795/non-caloric-sweetener-provides-magnetic-resonance-imaging-contrast-for-cancer-detection
#10
Puneet Bagga, Mohammad Haris, Kevin D'Aquilla, Neil E Wilson, Francesco M Marincola, Mitchell D Schnall, Hari Hariharan, Ravinder Reddy
BACKGROUND: Image contrast enhanced by exogenous contrast agents plays a crucial role in the early detection, characterization, and determination of the precise location of cancers. Here, we investigate the feasibility of using a non-nutritive sweetener, sucralose (commercial name, Splenda), as magnetic resonance imaging (MRI) contrast agent for cancer studies. METHODS: High-resolution nuclear-magnetic-resonance spectroscopy and MR studies on sucralose solution phantom were performed to detect the chemical exchange saturation transfer (CEST) property of sucralose hydroxyl protons with bulk water (sucCEST)...
May 30, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28525840/indole-carboxylic-acid-esters-of-melampomagnolide-b-are-potent-anticancer-agents-against-both-hematological-and-solid-tumor-cells
#11
Shobanbabu Bommagani, Jessica Ponder, Narsimha R Penthala, Venumadhav Janganati, Craig T Jordan, Michael J Borrelli, Peter A Crooks
A series of novel, heteroaryl carboxylic acid conjugates of the sesquiterpene melampomagnolide-B (MMB, 3) has been evaluated as antitumor agents against an NCI panel of 64 human hematopoetic and solid tumor cell lines. The indole-3-acrylic acid conjugate 7j and the indole-3-carboxylic acid conjugate 7k were found to be the most potent analogs in the series. Compounds 7j and 7k exhibited remarkable growth inhibition, with GI50 values in the range 0.03-0.30 μM and 0.04-0.28 μM, respectively, against the cell lines in the leukemia sub-panel, and GI50 values of 0...
August 18, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28503718/photodithazine-photodynamic-effect-on-viability-of-9l-lacz-gliosarcoma-cell-line
#12
Leticia C Fontana, Juliana G Pinto, André H C Pereira, Cristina P Soares, Leandro J Raniero, Juliana Ferreira-Strixino
Even with the advances of conventional treatment techniques, the nervous system cancer prognosis is still not favorable to the patient which makes alternative therapies needed to be studied. Photodynamic therapy (PDT) is presented as a promising therapy, which employs a photosensitive (PS) agent, light wavelength suitable for the PS agent, and molecular oxygen, producing reactive oxygen species in order to induce cell death. The aim of this study is to observe the PDT action in gliosarcoma cell using a chlorin (Photodithazine, PDZ)...
August 2017: Lasers in Medical Science
https://www.readbyqxmd.com/read/28457650/orthostatic-myoclonus-after-brain-tumor-radiation-insights-from-two-lesional-cases
#13
Jeremy K Cutsforth-Gregory, Julie E Hammack, Joseph Y Matsumoto
INTRODUCTION: Orthostatic myoclonus (OM) is a recognized syndrome of gait unsteadiness accompanied by lower limb myoclonus provoked by the assumption of an upright posture. OM typically affects the elderly and is often associated with neurodegenerative disease. We sought to review the clinical and electrophysiologic characteristics of OM due to brain tumor treatment, the first reported lesional cases of this rare disorder. METHODS: The database of the Mayo Clinic Rochester Movement Disorders Laboratory was searched for all patients diagnosed with OM from January 2007 to December 2016...
April 26, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28413542/lateral-ventricular-gliosarcoma-with-attachment-to-septum-pellucidum
#14
Pravin Salunke, Harnarayan Singh, Kim Vaiphei
Gliosarcomas are lesions with both glial and sarcomatous elements and are usually seen abutting the dura. Intraventricular location is extremely rare. Such an unusual intraventricular gliosarcoma is being reported.
January 2017: Asian Journal of Neurosurgery
https://www.readbyqxmd.com/read/28408749/high-prevalence-of-tp53-mutations-is-associated-with-poor-survival-and-an-emt-signature-in-gliosarcoma-patients
#15
Sung-Yup Cho, Changho Park, Deukchae Na, Jee Yun Han, Jieun Lee, Ok-Kyoung Park, Chengsheng Zhang, Chang Ohk Sung, Hyo Eun Moon, Yona Kim, Jeong Hoon Kim, Jong Jae Kim, Shin Kwang Khang, Do-Hyun Nam, Jung Won Choi, Yeon-Lim Suh, Dong Gyu Kim, Sung Hye Park, Hyewon Youn, Kyuson Yun, Jong-Il Kim, Charles Lee, Sun Ha Paek, Hansoo Park
Gliosarcoma (GS) is a rare variant (2%) of glioblastoma (GBM) that poses clinical genomic challenges because of its poor prognosis and limited genomic information. To gain a comprehensive view of the genomic alterations in GS and to understand the molecular etiology of GS, we applied whole-exome sequencing analyses for 28 GS cases (6 blood-matched fresh-frozen tissues for the discovery set, 22 formalin-fixed paraffin-embedded tissues for the validation set) and copy-number variation microarrays for 5 blood-matched fresh-frozen tissues...
April 14, 2017: Experimental & Molecular Medicine
https://www.readbyqxmd.com/read/28395087/retrospective-analysis-of-molecular-and-immunohistochemical-characterization-of-381-primary-brain-tumors
#16
Leomar Y Ballester, Gregory N Fuller, Suzanne Z Powell, Erik P Sulman, Keyur P Patel, Rajyalakshmi Luthra, Mark J Routbort
The classification of brain tumors has traditionally depended on microscopic examination of hematoxylin and eosin-stained tissue sections. The increased understanding of clinically relevant genetic alterations has led to the incorporation of molecular signatures as part of the diagnosis of brain malignancies. Advances in sequencing technologies have facilitated the use of next-generation sequencing (NGS) assays in clinical laboratories. We performed a retrospective analysis of sequencing results for 381 brain tumors tested by NGS at our institution using a validated, commercially available panel...
March 1, 2017: Journal of Neuropathology and Experimental Neurology
https://www.readbyqxmd.com/read/28340171/immunohistochemical-approach-to-the-differential-diagnosis-of-meningiomas-and-their-mimics
#17
Camille Boulagnon-Rombi, Clémence Fleury, Caroline Fichel, Sophie Lefour, Aude Marchal Bressenot, Guillaume Gauchotte
The differential diagnosis between meningioma and others tumors can be challenging. This study aimed to evaluate different immunohistochemical markers for the differential diagnosis between meningioma and their morphological mimics. Immunohistochemistry was performed on tissue microarray with antiepithelial membrane antigen (EMA), progesterone receptor, somatostatin receptor 2A (SSTR2A), CD34, STAT6, S100, SOX10, HMB45, MelanA, GFAP, inhibin, and BCL2 antibodies. One hundred and twenty-seven meningiomas, 26 solitary fibrous tumor/hemangiopericytomas (SFT/HPC), 39 schwannomas, 17 hemangioblastomas, 21 melanomas, 9 gliosarcomas, 5 neurofibromas, 9 peripheral primitive neuroectodermal tumors, 7 synovial sarcomas, and 5 malignant peripheral nerve sheath tumors were included in the microarray...
April 1, 2017: Journal of Neuropathology and Experimental Neurology
https://www.readbyqxmd.com/read/28327297/first-proof-of-bismuth-oxide-nanoparticles-as-efficient-radiosensitisers-on-highly-radioresistant-cancer-cells
#18
Callum Stewart, Konstantin Konstantinov, Sally McKinnon, Susanna Guatelli, Michael Lerch, Anatoly Rosenfeld, Moeava Tehei, Stéphanie Corde
This study provides the first proof of the novel application of bismuth oxide as a radiosensitiser. It was shown that on the highly radioresistant 9L gliosarcoma cell line, bismuth oxide nanoparticles sensitise to both kilovoltage (kVp) or megavoltage (MV) X-rays radiation. 9L cells were exposed to a concentration of 50μg.mL(-1) of nanoparticle before irradiation at 125kVp and 10MV. Sensitisation enhancement ratios of 1.48 and 1.25 for 125kVp and 10MV were obtained in vitro, respectively. The radiation enhancement of the nanoparticles is postulated to be a combination of the high Z nature of the bismuth (Z=83), and the surface chemistry...
November 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/28288892/mr-image-guided-delivery-of-cisplatin-loaded-brain-penetrating-nanoparticles-to-invasive-glioma-with-focused-ultrasound
#19
Kelsie F Timbie, Umara Afzal, Abhijit Date, Clark Zhang, Ji Song, G Wilson Miller, Jung Soo Suk, Justin Hanes, Richard J Price
Systemically administered chemotherapeutic drugs are often ineffective in the treatment of invasive brain tumors due to poor therapeutic index. Within gliomas, despite the presence of heterogeneously leaky microvessels, dense extracellular matrix and high interstitial pressure generate a "blood-tumor barrier" (BTB), which inhibits drug delivery and distribution. Meanwhile, beyond the contrast MRI-enhancing edge of the tumor, invasive cancer cells are protected by the intact blood-brain barrier (BBB). Here, we tested whether brain-penetrating nanoparticles (BPN) that possess dense surface coatings of polyethylene glycol (PEG) and are loaded with cisplatin (CDDP) could be delivered across both the blood-tumor and blood-brain barriers with MR image-guided focused ultrasound (MRgFUS), and whether this treatment could control glioma growth and invasiveness...
March 11, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28261869/intraventricular-gliosarcoma-with-dual-sarcomatous-differentiation-a-unique-case
#20
Rajalakshmi Poyuran, Nandeesh Bn, Yerasi Varun Kumar Reddy, Amey R Savardekar
Gliosarcoma, a variant of isocitrate dehydrogenase-wildtype glioblastoma, is largely a lobar surfacing neoplasm often with dural attachment. In this biphasic neoplasm, the sarcomatous component usually takes the form of fibrosarcoma or malignant fibrous histiocytoma. Heterologous sarcomatous differentiation is a rare phenomenon. Here, we present a case of gliosarcoma with liposarcomatous and myosarcomatous differentiation in a 68-year-old man which was purely intraventricular. This is the first report of such a morphologic pattern in this location...
March 6, 2017: Neuropathology: Official Journal of the Japanese Society of Neuropathology
keyword
keyword
64102
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"